<DOC>
	<DOCNO>NCT00000740</DOCNO>
	<brief_summary>To determine maximum tolerate dose ( MTD ) WR 6026 HIV-infected patient . To determine whether unexpected toxicity cause WR 6026 HIV-infected patient . To determine whether additional toxicity WR 6026 give 21 day rather 14 day . To investigate pharmacokinetics pharmacodynamics WR 6026 , particular examine potential correlation area concentration-time curve methemoglobinemia toxicity . In recent animal study , WR 6026 demonstrate inhibitory activity Pneumocystis carinii pneumonia ( PCP ) . This study ass safety tolerance drug HIV-infected patient PCP .</brief_summary>
	<brief_title>Escalating Multiple-Dose Safety Tolerance WR 6026 Hydrochloride HIV-Infected Subjects</brief_title>
	<detailed_description>In recent animal study , WR 6026 demonstrate inhibitory activity Pneumocystis carinii pneumonia ( PCP ) . This study ass safety tolerance drug HIV-infected patient PCP . Escalating dos WR 6026 study successive patient cohort . Four patient randomize active drug placebo 3:1 ratio dose level moderate toxicity demonstrate . If one patient give dose level experience WR 6026-related moderate bad toxicity , sample size subsequent dose level double . If two patient give dose level experience moderate dose-limiting toxicity , additional four patient ( randomized 3:1 ratio ) enter level , sample size subsequent dose level double . Dose escalation continue three six patient receive active drug give dose level experience dose-limiting worse toxicity , two six patient give dose level experience life-threatening toxicity . The MTD define dose immediately high dose study . Eight additional patient study presumed MTD confirm tolerance .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV antibody positive . CD4 cell count less 500/mm3 . Adequate general health . No significant deterioration performance status within past month . Prior treatment stable regimen antiretroviral medication least 4 week prior study . Prior Medication : Required : Stable regimen antiretroviral medication least 4 week prior study entry . Allowed : Aerosolized pentamidine PCP prophylaxis . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Intercurrent infection . Clinically significant abnormality EKG . Known hypersensitivity quinolines . Known hemoglobin M abnormality . Known NADH methemoglobin reductase deficiency . Positive test G6PD deficiency . Fever . Prior Medication : Excluded : Other systemic medication ( AZT , ddC , ddI , methadone , acyclovir , NSAIDs ) within 3 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>WR 6026</keyword>
</DOC>